# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Bloomberg
Rodman & Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $16 price t...
- Reuters Citing State TV
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a contract modification executing an option period by...
- Reuters
https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926 Senior Biden administrati...
https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523 Today, close to 100,000 mpox vaccine doses will arrive in the ...